Predictive genetic testing experience for myocilin primary open-angle glaucoma using the Australian and New Zealand Registry of Advanced Glaucoma

Genetics in Medicine

Volumn 16, Issue 7, 2014, Pages 558-563

  Souzeau, Emmanuelle ^a   Glading, Jodi ^a   Keane, Miriam ^a   Ridge, Bronwyn ^a   Zhou, Tiger ^a   Burdon, Kathryn P ^a   Craig, Jamie E ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Genetic counseling; Glaucoma; MYOC; Poag; Predictive genetic testing

Indexed keywords

MYOCILIN; CYTOSKELETON PROTEIN; EYE PROTEIN; GLYCOPROTEIN; TRABECULAR MESHWORK-INDUCED GLUCOCORTICOID RESPONSE PROTEIN;

ADULT; ARTICLE; AWARENESS; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE REGISTRY; EMOTION; FAMILY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GUILT; HAPPINESS; HIGH RISK POPULATION; HUMAN; MALE; MOTIVATION; OPEN ANGLE GLAUCOMA; PREDICTIVE GENETIC TESTING; QUESTIONNAIRE; VISUAL IMPAIRMENT; AGED; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; NEW ZEALAND; PROGNOSIS; PSYCHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYTOSKELETAL PROTEINS; EYE PROTEINS; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GLAUCOMA, OPEN-ANGLE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEW ZEALAND; PROGNOSIS; QUESTIONNAIRES;

EID: 84903782672     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.196     Document Type: Article

References (29)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267.
2. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661- 1669.
3. Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology 1998;105:733-739.
4. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-1279.
5. The effectiveness of intraocular pressure reduction in the treatment of normaltension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:498-505.
6. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-440.
7. Fingert JH, Héon E, Liebmann JM, et al. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Genet 1999;8:899-905.
8. Souzeau E, Burdon KP, Dubowsky A, et al. Higher prevalence of myocilin mutations in advanced glaucoma in comparison with less advanced disease in an Australasian disease registry. Ophthalmology 2013;120:1135- 1143.
9. Craig JE, Baird PN, Healey DL, et al. Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifier. Ophthalmology 2001;108:1607- 1620.
10. Shimizu S, Lichter PR, Johnson AT, et al. Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma. Am J Ophthalmol 2000;130:165-177.
11. Wei YT, Li YQ, Bai YJ, et al. Pro370Leu myocilin mutation in a Chinese pedigree with juvenile-onset open angle glaucoma. Mol Vis 2011;17:1449-1456.
12. Healey DL, Craig JE, Wilkinson CH, Stone EM, Mackey DA. Attitudes to predictive DNA testing for myocilin glaucoma: experience with a large Australian family. J Glaucoma 2004;13:304-311.
13. Souzeau E, Goldberg I, Healey PR, et al. The Australian and New Zealand Registry of Advanced Glaucoma: methodology and recruitment. Clin Experiment Ophthalmol 2012;40:569-575.
14. Hewitt AW, Mackey DA, Craig JE. Myocilin allele-specific glaucoma phenotype database. Hum Mutat 2008;29:207-211.
15. Young TK, Souzeau E, Liu L, et al. Compound heterozygote myocilin mutations in a pedigree with high prevalence of primary open-angle glaucoma. Mol Vis 2012;18:3064-3069.
16. Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. Science 1997;275:668-670.
17. Codori AM, Petersen GM, Miglioretti DL, et al. Attitudes toward colon cancer gene testing: factors predicting test uptake. Cancer Epidemiol Biomarkers Prev 1999;8(4 Pt 2):345-351.
18. Hadley DW, Jenkins J, Dimond E, et al. Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med 2003;163:573- 582.
19. Pre-symptomatic and predictive testing for genetic disorders. In: Human Genetics Society Of Australasia. ed2005. http://www.hgsa.org.au/documents/item/ 272.
20. Balmaña J, Stoffel EM, Emmons KM, Garber JE, Syngal S. Comparison of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes. J Med Genet 2004;41:e44.
21. Welkenhuysen M, Evers-Kiebooms G, Decruyenaere M, Claes E, Denayer L. A community based study on intentions regarding predictive testing for hereditary breast cancer. J Med Genet 2001;38:540-547.
22. Becker MH. The Health Belief Model and Personal Health Behaviour. Charles B. Slack: Thorofare, NJ, 1974.
23. Shiloh S, Ilan S. To test or not to test? Moderators of the relationship between risk perceptions and interest in predictive genetic testing. J Behav Med 2005;28:467-479.
24. Jacobsen PB, Valdimarsdottier HB, Brown KL, Offit K. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med 1997;59:459-466.
25. Peterson SK, Watts BG, Koehly LM, et al. How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet C Semin Med Genet 2003;119C:78-86.
26. Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A 2003;116A:11-19.
27. Tercyak KP, Peshkin BN, DeMarco TA, Brogan BM, Lerman C. Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns 2002;47:145-153.
28. Bradbury AR, Dignam JJ, Ibe CN, et al. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol 2007;25:3705-3711.
29. Pre-symptomatic testing in children and young adults. Human Genetics Society Of Australasia. ed2008. http://www.hgsa.org.au/documents/item/244.